Eli Lilly's migraine drug fails to meet main goal in post-approval study

Eli Lilly said on Friday its
drug Emgality did not meet the primary goal of superiority to
Pfizer Inc's Nurtec ODT in prevention of episodic
migraine in a post-approval study.
This was... | June 16, 2023

Related Keywords

Bengaluru ,Karnataka ,India ,Lilly Emgality ,Shinjini Ganguli ,Eli Lilly ,Leroy Leo ,Reuters ,Pfizer Inc Nurtec ,Pfizer Inc ,Eli Lilly And Company Stock Exchange ,News ,Information ,Press Release ,Mali ,Illy ,Aid ,N ,Friday ,Emgality ,Kid ,Lot ,Feet ,The ,Primary ,Goal ,F ,Superiority ,Nurtec ,Adt ,Prevention ,His Lly Us5324571083 ,